Omalizumab, both as a monotherapy and for oral immunotherapy (OIT), modulates specific T cell and dendritic cell (DC) subsets, increasing patient's reaction thresholds to common food allergens, ...

This article is part of “Innovations In: Sickle Cell Disease,” an editorially independent special report that was produced with financial support from Vertex Pharmaceuticals. Sickle cell disease was ...

A research team has developed an innovative technique that enables precise modification of specific proteins within complex biological environments. A research team led by Professor Seung Soo Oh and ...